
<!DOCTYPE html>
<!--[if lt IE 8]>      <html class="no-js nav theme-purple lt-ie10 lt-ie9 lt-ie8  " lang="en-us"> <![endif]-->
<!--[if IE 8]>         <html class="no-js nav theme-purple lt-ie10 lt-ie9  " lang="en-us"> <![endif]-->
<!--[if IE 9]>         <html class="no-js nav theme-purple lt-ie10  " lang="en-us"> <![endif]-->
<!--[if !IE]><!-->     <html class="no-js nav theme-purple  " lang="en-us" > <!--<![endif]-->	
    <head>
        <meta charset="utf-8" />
                		<title>CDC - Leishmaniasis - Resources for Health Professionals</title>
        		
        <meta name="description" content="Education and information about Leishmaniasis for Health Professionals focusing on prevention, control, signs, symptoms, diagnosis and treatment." />        <meta name="keywords" content="leishmaniasis, leishmania, sand fly, health professionals, doctors, health care providers, signs, symptoms, prevention, control, diagnosis, treatment" />		<meta name="viewport" content="width=device-width, initial-scale=1" />
		        <link rel="apple-touch-icon-precomposed" sizes="144x144" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-144x144.png" />
        <link rel="apple-touch-icon-precomposed" sizes="114x114" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-114x114.png" />
        <link rel="apple-touch-icon-precomposed" sizes="72x72" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-72x72.png" />
        <link rel="apple-touch-icon-precomposed" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-57x57.png" />
        <link rel="shortcut icon" href="../../../TemplatePackage/3.0/images/favicon.ico" />	
		
		<meta name="robots" content="index,follow" />
		<meta property="cdc:template_version" content="3.0" />
		<meta property="cdc:content-id" content="964784"/>
		<meta property="cdc:revision-id" content="18"/>
				<link rel="canonical" href="http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html"/>
				<!-- Internal Release Version # 3.7.2 -->
                			<link rel="stylesheet" href="../../../TemplatePackage/3.0/css/lib/bootstrap24.css" />
	<link rel="stylesheet" href="../../../TemplatePackage/3.0/css/app.css@3.2.1.7.css" />
	<!--[if gt IE 9]><!--><!--<![endif]-->
	<!--[if IE 7]>
		<link rel="stylesheet" href="/TemplatePackage/3.0/css/lib/font-awesome-ie7.css" />
	<![endif]-->
	<!--[if lt IE 9]>
		<link rel="stylesheet" href="/TemplatePackage/3.0/css/ie.css" />
	<![endif]-->
	<link rel="stylesheet" media="print" href="../../../TemplatePackage/3.0/css/print.css@3.2.1.7.css" />
	<script src="../../../TemplatePackage/3.0/js/libs/modernizr-latest.js"></script>
	<script>
		if(!Date.now){Date.now=function now(){return new Date().getTime()}}
		var page_timing = page_timing || {};
		page_timing.page_start = Date.now();
		function $$(e){if(window.$){e()}else{setTimeout(function(){$$(e)},50)}}
		// (function(){function e(e,t){var n=e.length;while(n--){if(e[n].indexOf(t)>-1){return e[n]}}return false}var t=e(document.getElementsByTagName("html")[0].className.split(" "),"theme-");if(t){var n=document.createElement("link");n.rel="stylesheet";n.type="text/css";n.media="screen";n.href="/TemplatePackage/3.0/css/themes/"+t+".css";document.getElementsByTagName("head")[0].appendChild(n)}})();

		var settings = {}, addthis = null;
	</script>

	<meta name="application-name" content="CDC.gov"/>
	<meta property="cdc:template_version" content="3.2.1.7" />
	<meta name="msapplication-TileColor" content="#0061aa" />
	<meta name="msapplication-square70x70logo" content="/TemplatePackage/3.0/images/Win8_tile_70x70.png" />
	<meta name="msapplication-square150x150logo" content="/TemplatePackage/3.0/images/Win8_tile_150x150.png" />
	<meta name="msapplication-wide310x150logo" content="/TemplatePackage/3.0/images/Win8_tile_310x150.png" />
	<meta name="msapplication-square310x310logo" content="/TemplatePackage/3.0/images/Win8_tile_310x310.png" />
	<meta name="viewport" content="width=device-width,initial-scale=1,shrink-to-fit=no">		        


 <style type="text/css" media="all"> 
@import url("https://www.cdc.gov/TemplatePackage/css/B/theme-green.css"); 
@import url("../../local/b/css/explore.css"); 
</style> 

        <meta name="DC.Format" content="text/html"><meta name="DC.Title" content="CDC - Leishmaniasis - Resources for Health Professionals"><meta name="DC.Description" content="Education and information about Leishmaniasis for Health Professionals focusing on prevention, control, signs, symptoms, diagnosis and treatment."><meta name="DC.Creator" content="CDC - Centers for Disease Control and Prevention"><meta name="DC.Date.Created" content="2010-08-15"><meta name="DC.Date.Reviewed" content="2010-08-15"> <style type="text/css"> h6 {   font-style:italic;   text-decoration:underline;  } </style> <script type="text/javascript">(function(H){H.id=H.id.replace('no-','')})(document.documentElement)</script>        		    </head>
    <body>
				



				<div id="skipmenu">
	<a href="index.html#searchTarget" class="skippy">Skip directly to search</a>
	<a href="index.html#azTab" class="skippy">Skip directly to A to Z list</a>
	<a href="index.html#nav-container" class="skippy">Skip directly to navigation</a>
	<a href="index.html#share-bar" class="skippy">Skip directly to page options</a>
	<a href="index.html#contentArea" class="skippy">Skip directly to site content</a>
</div>		    	<div id="wrapper">
    		
<!-- references to this removed intentionally -->
    		<header id="header">
    			<div class="container">
                    <div class="row">
                    	<div id="logo" class="span14">
                    		<!--iPad touch response and 508 voice reader issue currently under investigation -->
<a href="../../../index.html" title="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People">
	<img src="../../../TemplatePackage/3.0/images/masthead_subpage.svg" alt="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People" class="hidden-one" />
	<img src="../../../TemplatePackage/3.0/images/masthead_1-col.svg" alt="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People" class="visible-one" />
</a>

<!-- IOS9 iPad bug work around - make sure screen readers have a readable version of the logo to read
<a class="tp-sr-only" href="https://www.cdc.gov">Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People</a>
 -->
                    	</div>
                    	<!-- search -->
                    	<div id="searchArea" class="span10 hidden-one hidden-two">							
							
<div class="hidden"><a href="index.html#" name="searchTarget">Start of Search Controls</a></div>
<form class="searchForm" method="get" action="https://search.cdc.gov/search">
	<fieldset class="search-form-wrapper ">
		<legend>Search Form Controls</legend>
		<div class="search-form-checkbox">
			<label class="subset"><input type="checkbox" name="subset" checked="checked" value="">Search The CDC</label>
		</div>
		<div class="search-input-wrapper">
			<div class="search-buttons">
				<button class="btn-clear"><span class="sprite-14-close">Cancel</span></button>
				<button class="btn-submit"><span class="sprite-14-search-black">Submit</span></button>
				<input type="submit" value="Submit" style="display:none; visibility:hidden;" /> 
			</div>
			<div class="search-input">
				<label><input type="text" placeholder="SEARCH" name="query" /><span class="hidden">Search The CDC</span></label>
			</div>
		</div>
		<input type="hidden" name="utf8" value="&#x2713;" />
					<input type="hidden" name="affiliate" value="cdc-main" />
			</fieldset>
</form>							<div class="a2z-button pull-right hidden-one hidden-two"><a href="index.html#" id="azTab">CDC A-Z Index <span class="icon-angle-down"></span></a></div>
                    	</div>
                    </div>
                    	<div class="hidden-three hidden-four" id="mobile-menu">
		<ul>
			<li id="vp1-menu-button" class="border-bottom-white"><a href="index.html#" id="menu-nav"><span class="sprite-16-menu"></span>MENU</a></li>
			<li id="vp1-a2z-button" class="border-bottom-white"><a href="index.html#" id="menu-az">CDC A-Z</a></li>
			<li id="vp1-search-button" class="border-bottom-white"><a href="index.html#" id="menu-search"><span class="sprite-16-search-white"></span>SEARCH</a></li>
		</ul>
	</div>
<script>if (typeof page_timing !== 'undefined') { page_timing.menu_load = Date.now(); }</script>
                    <div class="a2z-bar hide">
                    	<div>
	<ul>
		<li><a href="../../../az/a.html">A</a></li>
		<li><a href="../../../az/b.html">B</a></li>
		<li><a href="../../../az/c.html">C</a></li>
		<li><a href="../../../az/d.html">D</a></li>
		<li><a href="../../../az/e.html">E</a></li>
		<li><a href="../../../az/f.html">F</a></li>
		<li><a href="../../../az/g.html">G</a></li>
		<li><a href="../../../az/h.html">H</a></li>
		<li><a href="../../../az/i.html">I</a></li>
		<li><a href="../../../az/j.html">J</a></li>
		<li><a href="../../../az/k.html">K</a></li>
		<li><a href="../../../az/l.html">L</a></li>
		<li><a href="../../../az/m.html">M</a></li>
		<li><a href="../../../az/n.html">N</a></li>
		<li><a href="../../../az/o.html">O</a></li>
		<li><a href="../../../az/p.html">P</a></li>
		<li><a href="../../../az/q.html">Q</a></li>
		<li><a href="../../../az/r.html">R</a></li>
		<li><a href="../../../az/s.html">S</a></li>
		<li><a href="../../../az/t.html">T</a></li>
		<li><a href="../../../az/u.html">U</a></li>
		<li><a href="../../../az/v.html">V</a></li>
		<li><a href="../../../az/w.html">W</a></li>
		<li><a href="../../../az/x.html">X</a></li>
		<li><a href="../../../az/y.html">Y</a></li>
		<li><a href="../../../az/z.html">Z</a></li>
		<li><a href="../../../az/0.html">#</a></li>
	</ul>
</div>
<script>if (typeof page_timing !== 'undefined') { page_timing.a2z_load = Date.now(); }</script>                    </div>
                    <div id="searchArea-two-column" class="span24 searchbar hide hidden-three hidden-four">
						  
<div class="hidden"><a href="index.html#" name="searchTarget">Start of Search Controls</a></div>
<form class="searchForm" method="get" action="https://search.cdc.gov/search">
	<fieldset class="search-form-wrapper ">
		<legend>Search Form Controls</legend>
		<div class="search-form-checkbox">
			<label class="subset"><input type="checkbox" name="subset" checked="checked" value="">Search The CDC</label>
		</div>
		<div class="search-input-wrapper">
			<div class="search-buttons">
				<button class="btn-clear"><span class="sprite-14-close">Cancel</span></button>
				<button class="btn-submit"><span class="sprite-14-search-black">Submit</span></button>
				<input type="submit" value="Submit" style="display:none; visibility:hidden;" /> 
			</div>
			<div class="search-input">
				<label><input type="text" placeholder="SEARCH" name="query" /><span class="hidden">Search The CDC</span></label>
			</div>
		</div>
		<input type="hidden" name="utf8" value="&#x2713;" />
					<input type="hidden" name="affiliate" value="cdc-main" />
			</fieldset>
</form>					</div>
                    <!--
	See the noscript include for modifying the emergency message. DO NOT add it here.
-->
<script>if (typeof page_timing !== 'undefined') { page_timing.emergency_load = Date.now(); }</script>
    				<div class="titlebar">
					 						<h2>


<a href="../../../nczved/divisions/dpd/index.html">Parasites</a> - <a href="../index.html">Leishmaniasis</a>

</h2>
					 					</div>
    				<!-- emergency -->
<div id="emergencyContainer">
	<!--
	<div class="alert alert-error en">
		<b>Attention!</b> Uncomment this section and place the emergency message here.
	</div>
	<div class="alert alert-error esp">
		<b>&#161;Atenci&#243;n!</b> Elimine el comentario de esta secci&#243;n y colocar el mensaje de emergencia aqu&#237;.
	</div>	
	-->
</div>

<!-- no script -->
<noscript>
	<div class="alert alert-block"> Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: <a href="../../../other/about_cdcgov.html">About CDC.gov</a>.</div>
</noscript>
<script>if (typeof page_timing !== 'undefined') { page_timing.noscript_load = Date.now(); }</script>
     			</div>
    		</header>
    		<div class="container">				
                <div id="content">
					<div class="row">
        				<!-- left nav -->
        				<div id="nav-container" class="hidden-one hidden-two span5">
    						<nav id="left" class="hidden-one hidden-two">
    							



<h3><a href="../../leishmaniasis.1.html">Leishmaniasis</a></h3>

<ul id="nav-primary">
<li><a href="../gen_info/index.html">General Information</a>
<ul>
<li><a href="../gen_info/faqs.html">Leishmaniasis FAQs</a></li>
</ul>
</li>

<li><a href="../epi.html">Epidemiology &#38; Risk Factors</a></li>

<li><a href="../biology.html">Biology</a></li>

<li><a href="../disease.html">Disease</a></li>

<li><a href="../diagnosis.html">Diagnosis</a></li>

<li><a href="../treatment.html">Treatment</a></li>

<li><a href="../prevent.html">Prevention &#38; Control</a></li>

<li><a href="index.html">Resources for Health Professionals</a></li>

<li><a href="../publications.html">Publications</a></li>

<li><a href="../add_resources.html">Additional Resources</a></li>
</ul>


    						</nav>
    						<div class="nav-related">
							


<div class="module-typeG emailupdates"><span class="sprite-24-govd-icon"></span><h4>Get Email Updates</h4><p>To receive email updates about this page, enter your email address:</p><form name="govdelivery" action="https://public.govdelivery.com/accounts/USCDC/subscribers/qualify"><fieldset><label><span class="hidden">Enter Email Address</span><input type="text" class="email" name="email" value="" onfocus="this.value=''" /></label><a class="explain" href="../../../emailupdates/index.html">What's this?</a><a href="javascript:quicksubscribe();return false;" class="button">Submit</a><noscript><a class="explain" href="../../../emailupdates/index.html">What's this?</a><label><span class="hidden">Submit Button</span><input type="submit" class="button submit" name="commit" value="Submit" /></label></noscript></fieldset></form></div>

    						



<div class="module page-curl blocklist">
<h4 style=" background-color: #B6B3DF;"><span>Information For:</span></h4>

<div class="inner">
<ul style=" list-style-type: none;">
<li class="last"><a href="http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/leishmaniasis-cutaneous.htm" target="_blank">Travelers</a></li>
</ul>
</div>

<div class="bot"><!-- --></div>
</div>

<div class="module page-curl blocklist">
<h4 style=" background-color: #B6B3DF;"><span>Related Links</span></h4>

<div class="inner">
<ul style=" list-style-type: none;">
<li><a href="../../az/index.html">Parasites A-Z Index</a></li>

<li><a href="../../glossary.html">Parasites Glossary</a></li>

<li><a href="../../../globalhealth/ntd/index.html">Neglected Tropical Diseases</a></li>

<li class="last"><a href="../../../dpdx/contact.html">Laboratory Diagnostic Assistance [DPDx]</a></li>
</ul>
</div>

<div class="bot"><!-- --></div>
</div>


							



							</div>    						    				
        				</div>
        				<div id="featureArea">
    						<div class="span19">
    							



    						</div>
        				</div>						
    					<div class="breadcrumbs hidden-one span19">
    						


<div class="bread-crumb hidden-one">
 <div class="prefix">
  <span>Parasites Home</span>
 </div>
</div>

    					</div>
						<div class="span19 pagetitle">	
    						    							<div class='syndicate'>
    						    						    							<div class='mSyndicate'>
    																					<h1>Resources for Health Professionals</h1>
															    						    							</div>
    						    						    							</div>
    												</div>
						<div id="share-bar" class="span19">		
    						<div class="socialmediabar">
								<div class="row">
            						<div class="hidden-one pull-right">
        								            							            							            						</div>	
    								<div class="span8">
    									<div id="socialMediaShareContainer">
	<div class="share_container noLinking">
	 	<a class="share_button_facebook" title="Facebook" href="index.html#"><span class="tp-sr-only">Recommend on Facebook</span><span id="share_facebook" class="facebookRecommend"> </span></a>
	 	<a class="share_button_twitter" title="Twitter" href="index.html#"><span class="tp-sr-only">Tweet</span><span id="share_twitter" class="twitterTweet"> </span></a>
		<a class="share_button" href="index.html#socialMediaShareContainer" ><img src="../../../TemplatePackage/3.0/images/social/addthis-32.png" alt="Share" /><span class="shareButtonEn tp-sr-only" aria-label="Share">Share</span><span class="shareButtonEs tp-sr-only" aria-label="Compartir">Compartir</span></a>
	</div>
</div>

<!-- target anchor for return to top feature in VP1 -->
<a id="content-start" tabindex="-1"></a>
    								</div>
								</div>
    						</div>
    					</div>	
    					<!-- body -->
    					<div id="body" class="span19">
    						<div id="contentArea" >								
        						        																						        						                                                                                            					            						<div class='syndicate'>
            					            					            						<div class='mSyndicate'>
            					            					        							<!-- InstanceBeginEditable name="content-main" -->
<div class="b">
<div><!-- -->
<div class="span19">
<div class="module-typeF">
<h3>Newly Released</h3>

<h5>“<a href="http://cid.oxfordjournals.org/content/63/12/e202.full.pdf+html" target="_blank">Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)</a>”</h5>
</div>
</div>
</div>
</div>

<div class="pull-right span6">
<div class="module-typeF" id="onthispage2">
<h4>On this Page</h4>

<ul class=" list-bullet">
<li><a href="index.html#disease">Disease</a>
<ul>
<li><a href="index.html#cl">Cutaneous Leishmaniasis</a></li>

<li><a href="index.html#ml">Mucosal Leishmaniasis</a></li>

<li><a href="index.html#vl">Visceral Leishmaniasis</a></li>
</ul>
</li>

<li><a href="index.html#dx">Diagnosis</a></li>

<li><a href="index.html#tx">Treatment</a>
<ul>
<li><a href="index.html#tx-gp">General Points</a></li>

<li><a href="index.html#tx-cl">Cutaneous Leishmaniasis</a></li>

<li><a href="index.html#tx-vl">Visceral Leishmaniasis</a></li>
</ul>
</li>

<li><a href="index.html#prevent">Prevention &#38; Control</a></li>
</ul>
</div>
</div>

<p>The term leishmaniasis encompasses multiple clinical syndromes, several of which are described here—the cutaneous, mucosal, and visceral forms, which result from infection of macrophages in the dermis, in the naso-oropharyngeal mucosa, and throughout the reticuloendothelial system, respectively. For all three forms, the infection can range from asymptomatic to severe. Cutaneous and mucosal leishmaniasis can cause substantial morbidity, whereas visceral leishmaniasis can be life threatening.</p>

<h4 id="disease">Disease</h4>

<p><a id="cl" name="cl"><!-- --></a></p>

<h5>Cutaneous Leishmaniasis</h5>

<p>This is the most common form of leishmaniasis, both in general and in U.S. travelers. Unless otherwise specified, cutaneous leishmaniasis refers to localized cutaneous leishmaniasis, rather than to much less common forms, such as diffuse cutaneous leishmaniasis and disseminated cutaneous leishmaniasis. Different <em>Leishmania</em> species cause Old World versus New World (American) cutaneous leishmaniasis. In the Old World (the Eastern Hemisphere), the etiologic agents include <em>Leishmania tropica</em>, <em>L. major</em>, and <em>L. aethiopica</em>, as well as <em>L. infantum</em> and <em>L. donovani</em>. The main species in the New World (the Western Hemisphere) are either in the <em>L. mexicana</em> species complex (<em>L. mexicana</em>, <em>L. amazonensis</em>, and <em>L. venezuelensis</em>) or the subgenus <em>Viannia</em> (<em>L. [V.] braziliensis</em>, <em>L. [V.] guyanensis</em>, <em>L. [V.] panamensis,</em> and <em>L. [V.] peruviana</em>). The <em>Viannia</em> subgenus is also referred to as the <em>L. (V.) braziliensis</em> species complex.</p>

<p>In general, cutaneous leishmaniasis causes skin lesions, which can persist for months, sometimes years. The skin lesions usually develop within several weeks or months after the exposure but occasionally first appear years later (for example, in the context of trauma or immunosuppression). The lesions typically evolve from papules to nodular plaques to ulcerative lesions, with a raised border and central depression, which can be covered by scab or crust; some lesions persist as nodules. The lesions usually are painless but can be painful, especially if ulcerative lesions become infected with bacteria or if the lesions are near a joint. The healing process typically results in atrophic scarring.</p>

<p>Even patients with localized cutaneous leishmaniasis quite commonly develop more than one primary lesion (on the same or different parts of the body), satellite lesions, regional lymphadenopathy (occasionally bubonic), and/or nodular lymphangitis (sporotrichoid-like subcutaneous nodules). Sometimes lymphadenopathy is noticed first, before skin lesions develop.</p>

<p class="topOPage"><a href="index.html">Back To Top</a></p>

<div class="pull-right span5">
<div class="module-typeN"><img alt="" src="https://www.cdc.gov/parasites/images/leishmaniasis/cl_ulcer.jpg" />
<p class="cdc-caption-text">Ulcerative skin lesion, with a raised outer border, on a Guatemalan patient who has cutaneous leishmaniasis. (Credit: B. Arana, MERTU, Guatemala)</p>
</div>
</div>

<p><a id="ml" name="ml"><!-- --></a></p>

<h5>Mucosal Leishmaniasis</h5>

<p>Mucosal leishmaniasis (also called <em>espundia</em>) traditionally refers to a metastatic sequela of New World cutaneous infection, which results from dissemination of parasites from the skin to the naso-oropharyngeal mucosa. Mucosal leishmaniasis is caused by species in the <em>Viannia</em> subgenus (especially <em>L. [V.] braziliensis</em> but also <em>L. [V.] panamensis</em> and sometimes <em>L. [V.] guyanensis</em>); it also can be caused by <em>L. (Leishmania) amazonensis</em>. Adequate systemic treatment of cutaneous leishmaniasis caused by these species is thought to reduce the risk for mucosal disease, but some risk may remain. The magnitudes and determinants (parasite and host factors) of the risks for mucosal dissemination and for mucosal disease per se are poorly understood; even for the same species (for example, <em>L. [V.] braziliensis</em>), the risks appear to vary among geographic regions in the Americas.</p>

<p>Mucosal leishmaniasis usually becomes clinically evident within several years (sometimes as long as decades) of the original cutaneous lesions, which typically were not treated at all or were treated suboptimally. However, mucosal and skin lesions may be noted concomitantly (<em>mucocutaneous leishmaniasis</em>), and some patients had subclinical cutaneous infection.</p>

<p>The initial manifestations of mucosal leishmaniasis usually are persistent, unusual nasal symptoms (such as stuffiness or bleeding), although oral or pharyngeal symptoms sometimes are noticed first. If untreated, the disease can progress to ulcerative destruction of the naso-oropharyngeal mucosa (such as perforation of the nasal septum).</p>

<p class="topOPage"><a href="index.html">Back To Top</a></p>

<p><a id="vl" name="vl"><!-- --></a></p>

<h5>Visceral Leishmaniasis</h5>

<p>The general term visceral leishmaniasis encompasses a broad spectrum of severity and manifestations. The onset can be chronic, subacute, or acute. Although the incubation period generally ranges from weeks to months, asymptomatic infection can become clinically manifest years to decades after the exposure in people who become immunocompromised for other medical reasons (such as HIV/AIDS). Visceral leishmaniasis usually is caused by the species <em>L. donovani</em> and <em>L. infantum</em> (<em>L. chagasi</em> generally is considered synonymous with <em>L. infantum</em>) and affects internal organs (particularly, spleen, liver, and bone marrow).</p>

<p class="list-leadIn">The stereotypical manifestations of clinically manifest visceral infection include:</p>

<ul class="bullet-list nolines list-indent">
<li>fever</li>

<li>weight loss (cachexia; wasting)</li>

<li>hepatosplenomegaly (usually, the spleen is more prominent than the liver)</li>

<li>pancytopenia—i.e., anemia, leukopenia, and thrombocytopenia</li>

<li>a high total protein level and a low albumin level, with hypergammaglobulinemia</li>
</ul>

<p class="list-leadOut">Lymphadenopathy may be noted, particularly in some geographic regions, such as Sudan.</p>

<p>HIV-coinfected patients may have atypical manifestations, such as involvement of the gastrointestinal tract and other organ systems.</p>

<p>The term <strong><em>kala-azar</em></strong>—which means black (<em>kala</em>) fever (<em>azar</em>) in Hindi—often is reserved for severe (advanced) cases of visceral leishmaniasis, although the terms kala-azar and visceral leishmaniasis sometimes are used interchangeably. If untreated, severe cases of visceral leishmaniasis typically are fatal, either directly from the disease or indirectly from complications, such as secondary (myco)bacterial infection or hemorrhage.</p>

<p>Some patients develop <strong>post kala-azar dermal leishmaniasis (PKDL)</strong>, a syndrome characterized by skin lesions (such as erythematous or hypopigmented macules, papules, nodules, and patches), typically first noticed and most prominent on the face, that develop at variable intervals after (or during) therapy for visceral leishmaniasis. PKDL is best described in cases of <em>L. donovani</em> infection in South Asia and East Africa. In general, PKDL is more common, develops earlier, and is less chronic in patients in East Africa. For example, in Sudan, PKDL is noted in up to 60% of patients, typically from 0 to 6 months after therapy for visceral leishmaniasis, and often heals spontaneously. In contrast, in South Asia, PKDL is noted in ~5-15% of patients, on average several years after initial therapy, and usually requires additional treatment. Persons with chronic PKDL can serve as important reservoir hosts of infection.</p>

<p class="topOPage"><a href="index.html">Back To Top</a></p>

<h4 id="dx">Diagnosis</h4>

<div class="pull-right span5">
<div class="module-typeN"><img alt="" src="https://www.cdc.gov/parasites/images/leishmaniasis/bone_marrow_biopsy.jpg" />
<p class="cdc-caption-text">Light-microscopic examination of a stained bone marrow specimen from a patient with visceral leishmaniasis—showing a macrophage (a special type of white blood cell) containing multiple <em>Leishmania</em> <strong>amastigotes</strong> (the tissue stage of the parasite). Note that each amastigote has a <strong>nucleus</strong> (red arrow) and a rod-shaped <strong>kinetoplast</strong> (black arrow). Visualization of the kinetoplast is important for diagnostic purposes, to be confident the patient has leishmaniasis. (Credit: CDC/DPDx)</p>
</div>
</div>

<p>Various laboratory methods can be used to diagnose leishmaniasis—to detect the parasite and to identify the <em>Leishmania</em> species. Some of the methods are available only in reference laboratories.</p>

<p class="list-leadIn">In the United States, CDC provides reference diagnostic services for leishmaniasis. For more details and <strong>instructions</strong> in this regard, see:</p>

<ul class="bulleted-links nolines list-indent">
<li><a href="https://www.cdc.gov/parasites/leishmaniasis/resources/pdf/cdc_diagnosis_guide_leishmaniasis_2016.pdf">Practical Guide for Laboratory Diagnosis of Leishmaniasis</a></li>
</ul>

<p>Leishmaniasis is diagnosed by detecting <em>Leishmania</em> parasites (or DNA) in tissue specimens—such as from skin lesions, for cutaneous leishmaniasis (see instructions), or from bone marrow, for visceral leishmaniasis (see note below)—via light-microscopic examination of stained slides, specialized culture techniques, or molecular methods.</p>

<p>Identification of the <em>Leishmania</em> species also can be important, particularly if more than one species is found where the patient lived or traveled and if they can have different clinical and prognostic implications. The species can be identified by various approaches, such as molecular methods and biochemical techniques (isoenzyme analysis of cultured parasites).</p>

<p>For visceral leishmaniasis, serologic testing can provide supportive evidence for the diagnosis. The performance of various serologic assays may vary by geographic region and by host factors (for example, the sensitivity of serologic testing generally is lower in HIV-coinfected patients, particularly if the HIV infection predated the <em>Leishmania</em> infection). Most serologic assays do not reliably distinguish between active and quiescent infection.</p>

<p>No leishmanin skin-test preparation has been approved for use in the United States.</p>

<div class="module rounders">
<div class="inner">
<div class="t"><!-- --></div>

<h5>Note</h5>

<div class="subColumns">
<div class="subc">
<p>For visceral leishmaniasis, although the diagnostic sensitivity is highest for splenic aspirates (&#62;95% vs. &#60;90% for other organs/tissues), the procedure can be associated with life-threatening hemorrhage, even if conducted under radiologic guidance. Bone marrow aspiration is much safer. Examples of other potential sources of specimens for diagnostic testing include liver, lymph node, and whole blood or buffy coat. Among HIV-infected patients, the parasite also may be found in atypical sites (such as the gastrointestinal tract).</p>

<!-- --></div>

<!--<br />
<br />
<div class="pull-right span5">
<div class="module-typeN"><img alt="" src="http://wcms.cdc.gov/Rhythmyx/assembler/render?sys_authtype=0&#38;sys_variantid=590&#38;sys_revision=1&#38;sys_contentid=954409&#38;sys_context=0&#38;sys_siteid=305" sys_dependentvariantid="590" sys_dependentid="954409" inlinetype="rximage" rxinlineslot="104" sys_siteid="305" sys_folderid="954407" sys_relationshipid="10648938" /> 

<p class="cdc-caption-text">Marked splenomegaly (enlargement/swelling of the spleen) in a patient in lowland Nepal who has visceral leishmaniasis. (Credit: C. Bern, CDC)</p>--></div>
</div>
</div>

<div class="b"><!-- -->
<p class="topOPage"><a href="index.html">Back To Top</a></p>

<p><a id="tx" name="tx"><!-- --></a></p>

<h4>Treatment</h4>

<div id="sync-content">
<h5 id="tx-gp">General Points</h5>

<p>The information provided here does <u>not</u>&#160;constitute a primer on treating leishmaniasis; rather, the focus is on basic principles and perspective, geared towards clinicians treating patients in the United States. Treatment decisions should be individualized, with expert consultation. In general, all clinically manifest cases of visceral leishmaniasis and mucosal leishmaniasis should be treated, whereas not all cases of cutaneous leishmaniasis require treatment.</p>

<p>The treatment approach depends in part on host and parasite factors. Some approaches/regimens are effective only against certain <em>Leishmania</em> species/strains and only in particular geographic regions. Even data from well-conducted clinical trials are not necessarily generalizable to other settings. Of particular note, data from the many clinical trials of therapy for visceral leishmaniasis in parts of India are not necessarily directly applicable to visceral leishmaniasis caused by <em>L. donovani</em> in other areas, to visceral leishmaniasis caused by other species, or to treatment of cutaneous and mucosal leishmaniasis.</p>

<p>Special groups (such as young children, elderly persons, pregnant/lactating women, and persons who are immunocompromised or who have other comorbidities) may need different medications or dosage regimens.</p>

<p>The relative merits of various treatment approaches/regimens can be discussed with CDC staff. In addition, in the United States, special considerations apply regarding the availability of particular medications to treat leishmaniasis. For example:</p>

<ul class="bullet-list nolines list-indent">
<li><strong>Pentavalent antimonial (Sb<sup>V</sup>) compounds</strong>—the traditional mainstays for treating leishmaniasis since the 1940s—are not licensed for U.S. commercial use. However, the Sb<sup>V</sup> compound <strong>sodium stibogluconate (Pentostam®)</strong> is available to U.S.-licensed physicians through the CDC Drug Service (404-639-3670), under an <strong>IND</strong> (Investigational New Drug) protocol approved by the Food and Drug Administration (<strong>FDA</strong>) and by CDC's Institutional Review Board. Although Pentostam® is not new or investigational, the IND mechanism makes it possible for CDC to stock and provide the drug in the United States. CDC's IND protocol covers intravenous (<strong>IV</strong>) and intramuscular (<strong>IM</strong>) administration (not intralesional). In the United States, the most common route of administration is IV (vs. IM), because the volume per dose is relatively high (for example, 14 mL for a 70-kg patient). Of note, Pentostam® is the only antileishmanial medication available through CDC.</li>

<li>One parenteral agent, <strong>liposomal amphotericin B</strong> (AmBisome®), which is administered by IV infusion, is FDA-approved for treatment of visceral leishmaniasis per se (i.e., the approved indications do not include cutaneous or mucosal leishmaniasis). This approval for visceral leishmaniasis dates back to 1997.</li>

<li>In March 2014, FDA <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm389671.htm">approved the oral agent <strong>miltefosine</strong></a> for treatment of cutaneous, mucosal, and visceral leishmaniasis caused by particular <em>Leishmania</em> species (see below for details), in adults and adolescents at least 12 years of age who weigh at least 30 kg (66 pounds). The FDA-approved treatment regimen for persons who weigh from 30 to 44 kg is as follows: one 50-mg oral capsule of miltefosine twice a day (total of 100 mg per day) for 28 consecutive days. The approved regimen for persons who weigh at least 45 kg (99 pounds) is one 50-mg capsule three times a day (total of 150 mg per day) for 28 consecutive days. Miltefosine is contraindicated in pregnant women. Women of reproductive potential should have a negative pregnancy test before starting therapy; they should be advised to use effective contraception during the treatment course and for 5 months thereafter. Nursing mothers should be advised not to breastfeed during the treatment course or for 5 months thereafter.</li>

<li>Some medications that might have merit for treating selected cases of leishmaniasis are available in the United States but the FDA-approved indications do not include leishmaniasis. Examples of such medications include the parenteral agents <strong>amphotericin B deoxycholate</strong> and <strong>pentamidine</strong> isethionate, as well as the orally administered "<strong>azoles</strong>" (<strong>ketoconazole</strong>, <strong>itraconazole</strong>, and <strong>fluconazole</strong>).</li>

<li>Other medications that might have merit for treating selected cases of leishmaniasis currently are not available in the United States (such as the parenteral formulation of the aminoglycoside <strong>paromomycin</strong>)—or—are potentially available only through special mechanisms. For example, particular topical formations of <strong>paromomycin</strong> may be available through compounding pharmacies or may be imported under a single-use treatment protocol.</li>
</ul>

<h5 id="tx-cl">Cutaneous Leishmaniasis</h5>

<p>Decisions about whether and how to treat should be individualized. The treatment approach depends in part on the <em>Leishmania</em> species/strain and the geographic area in which infection was acquired; the natural history of infection, the risk for mucosal dissemination/disease, and the drug susceptibilities in the pertinent setting; and the number, size, location, evolution, and other clinical characteristics of the patient's skin lesions.</p>

<p class="list-leadIn">Therapy of cutaneous leishmaniasis may be indicated to:</p>

<ul>
<li>decrease the risk for mucosal dissemination/disease (particularly for New World species in the <em>Viannia</em> subgenus; see <a href="index.html#disease">Disease</a>)</li>

<li>accelerate healing of the skin lesions</li>

<li>decrease the risk for relapse (clinical reactivation) of the skin lesions</li>

<li>decrease the local morbidity caused by large or persistent skin lesions, particularly those on the face or ears or near joints</li>

<li>decrease the reservoir of infection in geographic areas where infected persons (vs. non-human animals) serve as reservoir hosts (such as in Kabul, Afghanistan, and other <em>Leishmania tropica</em>-endemic areas, where transmission is anthroponotic)</li>
</ul>

<p class="list-leadOut">In general, the first sign of a therapeutic response to adequate treatment is decreasing induration (lesion flattening). The healing process for large, ulcerative lesions often continues after the end of therapy. Relapse (clinical reactivation) typically is noticed first at the margin of the lesion.</p>

<h6>Systemic therapy (parenteral)</h6>

<p>For <strong>pentavalent antimonial (Sb<sup>V</sup>) therapy</strong>, see above about CDC's IND protocol for <strong>sodium stibogluconate (Pentostam®)</strong>. The standard daily dose is 20 mg of Sb<sup>V</sup> per kg, administered IV or IM. The traditional duration of therapy is 20 days for cutaneous leishmaniasis (10 days may suffice in some settings) and 28 days for mucosal (and visceral) leishmaniasis. For some patients, adjustment of the daily dose or the duration of therapy may be indicated.</p>

<p>Conventional <strong>amphotericin B deoxycholate</strong> traditionally has been used as rescue therapy for cutaneous (and mucosal) leishmaniasis. <strong>Lipid formulations of amphotericin B</strong> typically are better tolerated than conventional amphotericin B. However, the data supporting their use for treatment of cutaneous (and mucosal) leishmaniasis are anecdotal; standard dosage regimens have not been established. When lipid formulations (e.g., liposomal amphotericin B) have been used for treatment of cutaneous leishmaniasis, patients typically have received 3 mg per kg daily, by IV infusion, for a total of 6 to 10 or more doses.</p>

<p>In the United States, <strong>pentamidine</strong> isethionate is uncommonly used for treatment of cutaneous leishmaniasis. Its limitations include the potential for irreversible toxicity and variable effectiveness.&#160;</p>

<h6>Systemic therapy (oral)</h6>

<p class="list-leadIn">In March 2014, FDA approved the oral agent <strong>miltefosine</strong> for treatment of cutaneous leishmaniasis in adults and adolescents who are not pregnant or breastfeeding. The FDA-approved indications are limited to infection caused by three particular species, all three of which are New World species in the <em>Viannia</em> subgenus—namely, <em>Leishmania</em> (<em>V.</em>) <em>braziliensis</em>, <em>L.</em> (<em>V.</em>) <em>panamensis</em>, and <em>L.</em> (<em>V.</em>) <em>guyanensis</em>. Even for these species, the effectiveness of miltefosine has been variable in different geographic regions. Use of miltefosine for treatment of infection caused by other <em>Leishmania</em> species in the New World or by any species in the Old World would constitute off-label use, as would treatment of children less than 12 years of age. See above for additional perspective and considerations regarding miltefosine.</p>

<p>The "azoles" <strong>ketoconazole</strong>, <strong>itraconazole</strong>, and <strong>fluconazole</strong>—administered orally—have been used with mixed results, in various settings. For example:</p>

<ul class="bullet-list nolines list-indent">
<li><strong>Ketoconazole</strong> (adult regimen: 600 mg daily for 28 days) showed modest activity against <em>L. mexicana</em> and <em>L. (V.) panamensis</em> infection in small studies in Guatemala and Panama, respectively. However, <strong>itraconazole</strong> (adult regimen: 200 mg twice daily for 28 days) was ineffective against <em>L. (V.) panamensis</em> infection in a clinical trial in Colombia.</li>

<li>Use of <strong>fluconazole</strong> (adult regimen: 200 mg daily for 6 weeks) for treatment of <em>L. major</em> infection in various countries in the Old World has been associated with mixed results. Preliminary data from Iran suggest that a higher daily dose (400 vs. 200 mg) might be more effective against <em>L. major</em> infection. Preliminary, uncontrolled data from northeastern Brazil suggest that a regimen of 8 mg per kg daily for 4 to 6 weeks might be effective against <em>L. (V.) braziliensis</em> infection in that region.</li>
</ul>

<h6>Local therapy</h6>

<p>Some cases of cutaneous leishmaniasis without risk for mucosal dissemination/disease might be candidates for local therapy, in part depending on the number, location, and characteristics of the skin lesions. Examples of local therapies that might have utility in some settings include cryotherapy (with liquid nitrogen), thermotherapy (use of localized current field radiofrequency heat), intralesional administration of Sb<sup>V</sup> (to date, not covered by CDC's IND protocol for Pentostam®), and topical application of paromomycin (such as an ointment containing 15% paromomycin/12% methylbenzethonium chloride in soft white paraffin; not commercially available in the United States).</p>

<h5 class="list-leadOut" id="tx-vl">Visceral Leishmaniasis</h5>

<p>The use of highly effective systemic therapy for leishmaniasis is important, as is supportive care—for example, therapy for malnutrition, anemia/bleeding, and intercurrent infections. For HIV-coinfected patients, antiretroviral therapy (ART) should be started or optimized according to standard practice; appropriate use of ART delays relapses and improves survival.</p>

<p><strong>Liposomal amphotericin B</strong> is FDA-approved for treatment of visceral leishmaniasis. Although various regimens have been suggested in the published literature, the FDA-approved regimen for immunocompetent patients consists of 3 mg per kg daily, by IV infusion, on days 1–5, 14, and 21 (total dose of 21 mg/kg). The FDA-approved regimen for immunosuppressed patients consists of 4 mg per kg daily on days 1–5, 10, 17, 24, 31, and 38 (total dose of 40 mg/kg). Some immunosuppressed patients may need even higher total doses and/or secondary prophylaxis (chronic maintenance therapy), in particular, HIV-coinfected patients with CD4 counts &#60;200 cells/mm<sup>3</sup>. However, standard approaches to antileishmanial treatment and secondary prophylaxis have not been established—for example, the optimal agent, dose, and dosing interval for maintenance therapy.</p>

<p><strong>Conventional amphotericin B deoxycholate</strong> is highly effective therapy for visceral leishmaniasis but generally is more toxic than liposomal amphotericin B. Immunocompetent patients typically receive 0.5 to 1.0 mg per kg—either daily or every other day—by IV infusion—for a total dose of approximately 15 to 20 mg per kg. Longer courses of therapy may be indicated for some patients.</p>

<p><strong>Pentavalent antimonial (Sb<sup>V</sup>) therapy</strong> generally remains highly effective in most regions, with the notable exception of parts of South Asia. See above about CDC's IND protocol for <strong>sodium stibogluconate</strong> (<strong>Pentostam®)</strong>. The standard dosage regimen for immunocompetent patients consists of 20 mg of Sb<sup>V</sup> per kg daily, IV or IM, for 28 days. For some patients, adjustment of the daily dose or the duration of therapy may be indicated.</p>

<p>Other parenteral agents that have merit in some settings include <strong>paromomycin</strong> sulfate (the chemical equivalent of aminosidine), which is not available for parenteral administration in the United States—and—<strong>pentamidine</strong> isethionate, a second-line agent whose limitations include suboptimal effectiveness (most notably, in parts of South Asia) and the potential for irreversible toxicity.</p>

<p><strong>Miltefosine</strong> is considered the first highly active oral agent for visceral leishmaniasis. In March 2014, FDA approved miltefosine for treatment of visceral leishmaniasis caused by <em>Leishmania donovani</em>, in adults and adolescents who are not pregnant or breastfeeding. Use of miltefosine for visceral leishmaniasis caused by other species (e.g., <em>L. infantum</em>) would constitute off-label use, as would treatment of children less than 12 years of age. See above for additional perspective and considerations regarding miltefosine.</p>
</div>

<!-- END SYNC CONTENT -->
<p class="topOPage"><a href="index.html">Back To Top</a></p>

<h4 class="list-leadOut" id="prevent">Prevention &#38; Control</h4>

<p>No vaccines or drugs to prevent infection are available.</p>

<p>The best way for travelers to prevent infection is to protect themselves from sand fly bites. Personal protective measures include minimizing nocturnal outdoor activities, wearing protective clothing, and applying insect repellent to exposed skin.</p>

<p>In general, prevention and control measures must be tailored to the local setting and typically are difficult to sustain. Control measures against sand fly vectors or animal reservoir hosts might be effective in some settings.</p>

<p>In many geographic areas where leishmaniasis is found in people, infected people are not needed to maintain the transmission cycle of the parasite in nature; animal reservoir hosts (such as rodents or dogs), along with sand flies, maintain the cycle. For example, in <em>L. infantum/L. chagasi</em>-endemic regions, dogs serve as the main reservoir hosts; control strategies for such areas are being evaluated.</p>

<p>In some parts of the world, infected people are needed to maintain the cycle; this type of transmission (human—sand fly—human) is called <strong>anthroponotic</strong>. For example, in the Indian Subcontinent (South Asia), the transmission of <em>L. donovani</em> is anthroponotic. In such areas, early detection and effective treatment of patients can serve as a control measure; suboptimal treatment can lead to development and spread of drug resistance. Because the transmission is intra- and peridomiciliary (rather than sylvatic), spraying dwellings with residual-action insecticides and using bed nets treated with long-lasting insecticides may be protective.</p>

<p class="moreon"><strong>More on:</strong> <a href="http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/leishmaniasis-cutaneous.htm">Travelers and Leishmaniasis</a></p>

<p class="topOPage"><a href="index.html">Back To Top</a></p>

<!-- InstanceEndEditable --><!-- /end .main-inner -->
<div id="linkPolicy"><!-- --></div>

<!-- /end #content-main--></div>
             					            					            						</div>
            					            					            						</div>
            													        						                                                                                        						                                                                								<!-- Related Nav Area -->
								<div class="nav-related hidden-three hidden-four">
									


<div class="module-typeG emailupdates"><span class="sprite-24-govd-icon"></span><h4>Get Email Updates</h4><p>To receive email updates about this page, enter your email address:</p><form name="govdelivery" action="https://public.govdelivery.com/accounts/USCDC/subscribers/qualify"><fieldset><label><span class="hidden">Enter Email Address</span><input type="text" class="email" name="email" value="" onfocus="this.value=''" /></label><a class="explain" href="../../../emailupdates/index.html">What's this?</a><a href="javascript:quicksubscribe();return false;" class="button">Submit</a><noscript><a class="explain" href="../../../emailupdates/index.html">What's this?</a><label><span class="hidden">Submit Button</span><input type="submit" class="button submit" name="commit" value="Submit" /></label></noscript></fieldset></form></div>

									



<div class="module page-curl blocklist">
<h4 style=" background-color: #B6B3DF;"><span>Information For:</span></h4>

<div class="inner">
<ul style=" list-style-type: none;">
<li class="last"><a href="http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/leishmaniasis-cutaneous.htm" target="_blank">Travelers</a></li>
</ul>
</div>

<div class="bot"><!-- --></div>
</div>

<div class="module page-curl blocklist">
<h4 style=" background-color: #B6B3DF;"><span>Related Links</span></h4>

<div class="inner">
<ul style=" list-style-type: none;">
<li><a href="../../az/index.html">Parasites A-Z Index</a></li>

<li><a href="../../glossary.html">Parasites Glossary</a></li>

<li><a href="../../../globalhealth/ntd/index.html">Neglected Tropical Diseases</a></li>

<li class="last"><a href="../../../dpdx/contact.html">Laboratory Diagnostic Assistance [DPDx]</a></li>
</ul>
</div>

<div class="bot"><!-- --></div>
</div>


								</div>
    							<!-- Persistent Content Area -->
    							<div id="content-secondary">
                                    



            						


<!-- EMPTY SSI -->

    							</div><!-- /end #content-secondary -->
    						</div><!-- /end #contentArea -->
    					</div><!-- /end body -->	
					</div>
					<div class="row">
						<div class="span24 visible-one">
																											</div>
					</div>
					<div class="row">
						<div class="span24">
                            <div id="plugin-legend" class="pluginOff">
	<h5>File Formats Help:</h5><span><a href="../../../Other/plugins/index.html">How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?</a></span>
	<ul>
		<li class="plugin-pdf"><a href="../../../Other/plugins/index.html#pdf"><span class="sprite-16-pdf">Adobe PDF file</span></a></li>
		<li class="plugin-ppt"><a href="../../../Other/plugins/index.html#ppt"><span class="sprite-16-ppt">Microsoft PowerPoint file</span></a></li>
		<li class="plugin-word"><a href="../../../Other/plugins/index.html#doc"><span class="sprite-16-word">Microsoft Word file</span></a></li>
		<li class="plugin-excel"><a href="../../../Other/plugins/index.html#xls"><span class="sprite-16-excel">Microsoft Excel file</span></a></li>
		<li class="plugin-wmv"><a href="../../../Other/plugins/index.html#wmv"><span class="sprite-16-wmv">Audio/Video file</span></a></li>
		<li class="plugin-qt"><a href="../../../Other/plugins/index.html#qt"><span class="sprite-16-qt">Apple Quicktime file</span></a></li>
		<li class="plugin-real"><a href="../../../Other/plugins/index.html#ram"><span class="sprite-16-rp">RealPlayer file</span></a></li>
		<li class="plugin-text"><a href="../../../Other/plugins/index.html#text"><span class="sprite-16-txt">Text file</span></a></li>
		<li class="plugin-zip"><a href="../../../Other/plugins/index.html#zip"><span class="sprite-16-zip">Zip Archive file</span></a></li>
		<li class="plugin-sas"><a href="../../../Other/plugins/index.html#sas"><span class="sprite-16-sas">SAS file</span></a></li>
		<li class="plugin-epub"><a href="../../../Other/plugins/index.html#epub"><span class="sprite-16-ebook">ePub file</span></a></li>
		<li class="plugin-ris"><a href="../../../Other/plugins/index.html#ris"><span class="sprite-16-ris">RIS file</span></a></li>
	</ul>
</div>
						</div>
					</div>
					<!-- date stamp -->
					<div id="datestamp" class="row" itemscope="itemscope" itemtype="http://schema.org/WebPage">
						<div class="span24">
    						<ul> 
            					            						<li class="last-reviewed">Page last reviewed: <span itemprop="lastReviewed">December 1, 2016</span></li>
            													            					            						<li class="last-updated">Page last updated: <span itemprop="dateModified">December 9, 2016</span></li>
            					        							<li class="content-source">Content source:
    									



<ul class="noindent">
<li class="" itemprop="sourceOrganization" itemscope="itemscope" itemtype="http://schema.org/Organization"><a href="../../../globalhealth.1.html">Global Health</a> - <a href="../../../nczved/divisions/dpd/index.html">Division of Parasitic Diseases</a></li>
</ul>


        							</li>
									



    						</ul>
						</div>
					</div>					
				</div><!-- /end #content -->
			</div><!-- /.container for content -->					
			<!-- footer -->
				<footer id="footer" class="cdcSlimFooter">
	
 <!-- include eng footerSubSocialMedia.html -->
<div class="socialMedia">
	<div class="container">
		<nav class="followcdc">
			<ul>
				<li><a href="../../../Other/emailupdates.1.html"><span class="sprite-24-govd"></span><span class="tp-sr-only">Email</span></a></li>
				<li><a href="https://www.facebook.com/CDC" target="_blank"><span class="sprite-24-facebook"></span><span class="tp-sr-only">Recommend</span></a></li>
				<li><a href="https://twitter.com/CDCgov" target="_blank"><span class="sprite-24-twitter"></span><span class="tp-sr-only">Tweet</span></a></li>
				<li><a href="https://www.youtube.com/user/CDCstreamingHealth" target="_blank"><span class="sprite-24-youtube"></span><span class="tp-sr-only">YouTube</span></a></li>
				<li><a href="https://www.instagram.com/CDCgov/" target="_blank"><span class="sprite-24-instagram"></span><span class="tp-sr-only">Instagram</span></a></li>
			</ul>
		</nav>
		<nav class="cdcmedia">
			<ul>
				<li><a href="https://www2c.cdc.gov/podcasts"><span class="sprite-24-listen"></span><span class="tp-sr-only">Listen</span></a></li>
				<li><a href="../../../cdctv.1.html"><span class="sprite-24-watch"></span><span class="tp-sr-only">Watch</span></a></li>
				<li><a href="https://www2c.cdc.gov/podcasts/rss.asp"><span class="sprite-24-rss"></span><span class="tp-sr-only">RSS</span></a></li>
			</ul>
		</nav>
	</div>
</div>
 <!-- /include eng footerSubSocialMedia.html -->

	<div class="container">
		<div class="cdcLinks">
			<div class="container">
				<ul>
					
<!-- include eng footerSubCdcLinks.html-->
<li>
	<nav>
		<h6 class="hidden-four hidden-three">ABOUT <span class="icon-plus visible-one pull-right"></span></h6>
		<ul class="hidden-one">
			<li><a href="../../../about/default.htm">About CDC</a></li>
			<li><a href="https://jobs.cdc.gov">Jobs</a></li>
			<li><a href="../../../funding.1.html">Funding</a></li>
		</ul>
	</nav>
</li>
<li>
	<nav>
		<h6 class="hidden-four hidden-three">LEGAL <span class="icon-plus visible-one pull-right"></span></h6>
		<ul class="hidden-one">
			<li><a href="../../../Other/policies.html">Policies</a></li>
			<li><a href="../../../Other/privacy.html">Privacy</a></li>
			<li><a href="../../../od/foia.1.html">FOIA</a></li>
			<li><a href="../../../eeo/nofearact/index.htm">No Fear Act</a></li>
			<li><a href="https://oig.hhs.gov" class="no-link">OIG</a></li>
		</ul>
	</nav>
</li>
<!--/ include eng footerSubCdcLinks.html-->

				</ul>
			</div>
		</div>
		<div class="cdcContact">
			<div class="container">
				<ul>
					<li class="local-contact">
						
 <!-- include eng footerSubGlobalContact1.html -->
<section>
	<address class="address" itemscope="itemscope" itemtype="https://schema.org/Organization">
		<span class="value" itemprop="address" itemscope="itemscope" itemtype="https://schema.org/PostalAddress">
			<span itemprop="streetAddress">1600 Clifton Road</span>
			<span itemprop="addressLocality">Atlanta</span>,
			<span itemprop="addressRegion">GA</span>
			<span itemprop="postalCode">30329-4027</span>
			<span itemprop="addressCountry">USA</span>
		</span><br />
		<span class="value" itemprop="telephone">800-CDC-INFO (800-232-4636)</span>,
		<span class="value" itemprop="telephone">TTY: 888-232-6348</span><br />
		<span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://wwwn.cdc.gov/dcs/RequestForm.aspx" class=" default no-link">Email CDC-INFO</a></span>
		</span>
	</address>
</section>
 <!-- /include eng footerSubGlobalContact1.html -->

					</li>
					<li class="contact">
						
 <!-- include eng footerSubGlobalContact2.html -->
<section>
	<address class="address" itemscope="itemscope" itemtype="https://schema.org/Organization">
		<span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://www.hhs.gov" class="no-link">U.S. Department of Health & Human Services</a></span>
		</span><br />
        <span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
        	<span itemprop="url"><a href="https://www.hhs.gov/open" class="no-link">HHS/Open</a></span>
        </span><br />
        <span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://www.usa.gov/" class="no-link">USA.gov</a></span>
		</span>
	</address>
</section>
 <!-- /include eng footerSubGlobalContact2.html -->

					</li>
				</ul>
			</div>
		</div>
	</div>
</footer>			<!-- /#footer -->
			<div id="totop" class="off visible-one">Top</div>
        </div>
		<script>page_timing.libs_start = Date.now();</script><script src="../../../TemplatePackage/3.0/js/libs.min.js@3.2.1.7"></script><script>page_timing.libs_end = Date.now();page_timing.core_start = Date.now();</script><script src="../../../TemplatePackage/3.0/js/core.min.js@3.2.1.7"></script><script>page_timing.core_end = Date.now();</script><!-- Start Site Settings Overrides -->
<script>
CDC.Constants.set("flexSliderVideoDomains", ['youtube.com','ytimg.com','vimeocdn.com'], 'es');
	CDC.Global.settings.includeCDCInBreadCrumbBar=true;
	CDC.Global.settings.includePageInBreadCrumbBar=true;
	CDC.Global.settings.catchJSErrors=true;
</script>
<!-- End Site Settings Overrides --><script>page_timing.app_start = Date.now();</script><script src="../../../TemplatePackage/3.0/js/app.min.js@3.2.1.7"></script><script>page_timing.app_end = Date.now();</script>		
		        			<!-- Begin Survey scripts -->
<script src="../../../JScript/foresee/foresee-trigger.js"></script>
<script src="../../../JScript/foresee-variables.js"></script>
<!-- End Survey scripts -->
			
            <script>if (typeof page_timing !== 'undefined') { page_timing.metrics_start = Date.now(); }</script>
<!-- xxxxxxxxxxxxxxxxxx METRICS code begins here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->
<div id="metrics">

<!-- Begin Google DAP inclusion -->
<script type="text/javascript" id="_fed_an_ua_tag" src="../../../JScript/metrics/google/Universal-Federated-Analytics-Min.js@agency=HHS&amp;subagency=CDC"></script>
<!-- End Google DAP inclusion -->

<!-- Begin Template Package Custom Interactions -->
<script type="text/javascript" src="../../../JScript/metrics/rd_custom_interactions.js"></script>
<!-- End Template Package Custom Interactions -->

<!-- SiteCatalyst code version: H.21. -->
<script src="../../../JScript/metrics/topic_levels.js"></script>
<script src="../../../JScript/metrics/s_code_v21_cdcgov.js"></script>
<script>

	enquire.register(CDC.Global.selectors.vp1, function() {
		s.prop49 = 1;
	});
	enquire.register(CDC.Global.selectors.vp2, function() {
		s.prop49 = 2;
	});
	enquire.register(CDC.Global.selectors.vp3, function() {
		s.prop49 = 3;
	});
	enquire.register(CDC.Global.selectors.vp4, function() {
		s.prop49 = 4;
	});

            
            <B>Error processing SSI file</B><BR>
            
                        
            s.prop2=window.location.href;
s.prop26=document.title;
s.prop30=document.title;
s.prop31=window.location.href;
s.prop46=window.location.href;
s.server=window.location.hostname;

// Update the level variables here.
updateVariables(s);

/************* DO NOT ALTER ANYTHING BELOW THIS LINE ! **************/
var s_code=s.t();



if(s_code) {
	document.write(s_code);
}



if (document.location.protocol) {


	var cookieManagment = {
		getUuid : function (strPrefix) {
			strPrefix = strPrefix || "";
			var d = new Date();
			var seconds = Math.round(d.getTime() / 1000);
			return strPrefix + Math.floor((1 + Math.random()) * 0x10000).toString(16).substring(1) + "-" + seconds.toString();
		},
		setCookie : function (cname, cvalue, exdays, domain) {
			domain = domain || ".cdc.gov";
			var d = new Date();
			d.setTime(d.getTime() + (exdays*24*60*60*1000));
			var expires = "expires="+ d.toUTCString();
			document.cookie = cname + "=" + cvalue + ";" + expires + ";domain=" + domain + ";path=/";
		},
		getCookie : function (cname) {
			var name = cname + "=";
			var ca = document.cookie.split(';');
			var i = ca.length;
			while (i --) {
				var c = ca[i];
				while (c.charAt(0)==' ') {
					c = c.substring(1);
				}
				if (c.indexOf(name) == 0) {
					return c.substring(name.length,c.length);
				}
			}
			return "";
		},
		init : function () {



			var currCookieVal = cookieManagment.getCookie('cdc_s_vi');

			if (!currCookieVal.length || currCookieVal.indexOf('[CS]v1') != -1) {
				var newCookieVal = cookieManagment.getUuid('[CS]v2') + "-" + cookieManagment.getUuid('');
				cookieManagment.setCookie("cdc_s_vi", newCookieVal, 7);
				return newCookieVal;
			}
			return currCookieVal;
		}
	};


	var cdcSessionID = cookieManagment.init();

	s3 = s_gi("cdcgovvistorid");

	var sKey, override = {
		fun: "cdcgovvistorid",
		trackingServer: "cdc.112.2o7.net"
	};

	s3.visitorID = cdcSessionID;

	for (sKey in s) {
		if (s.hasOwnProperty(sKey)) {
			if (override.hasOwnProperty(sKey)) {
				s3[sKey] = override[sKey];

			} else {

			}
		}
	}
	updateVariables(s3);


	var s_code_uvid = s3.t();
	if(s_code_uvid) {
		document.write(s_code_uvid);
	}
}




</script>
<script type="text/javascript">
if(navigator.appVersion.indexOf('MSIE')>=0) { document.write(unescape('%3C')+'\!-'+'-'); }
</script>
<noscript><a href="http://www.omniture.com"><img src="https://smtrics.cdc.gov/b/ss/cdcgov/1/H.21--NS/01/H.21--NS/0" height="1" width="1" alt="Web Analytics" /></a></noscript><!--/DO NOT REMOVE/-->
<!-- End SiteCatalyst code version: H.21. -->
<!-- Begin Template Package DigitalGov Search Support -->
<script type="text/javascript" src="../../../JScript/rd_search.js"></script>
<!-- End Template Package DigitalGov Search Support -->
</div>
<!-- xxxxxxxxxxxxxxxxxx METRICS code ends here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->
<script>if (typeof page_timing !== 'undefined') { page_timing.metrics_end = Date.now(); }</script>
				


<!--[if IE]>
<script defer language="javascript" type="text/javascript">
		var cdcLeftNav = new CDC.LeftNav("nav-primary");
		cdcLeftNav.render();
</script>
<![endif]-->
<!--[if ! IE]><!-->
<script language="javascript" type="text/javascript">
$().ready(function(){
		var cdcLeftNav = new CDC.LeftNav("nav-primary");
		cdcLeftNav.render();
});
</script>
<!--<![endif]-->

    	



						    </body>
	</html>
